Celltrion announced Friday that it has entered into a contract manufacturing organization (CMO) agreement with Baxter BioPharma Solutions (BPS), a business unit of Baxter, for the consignment production of its biosimilars in the U.S.
Celltrion plans to increase the stable supply of its biosimilar products in America, encouraged by the expansion of its market share in the U.S. for an antibody biosimilar for the treatment of autoimmune diseases.
Celltrion's hit product, Remsima, has a market share of more than 46 percent in Europe and is increasing its prescription rate steadily in the U.S., too.
The company plans to diversify its production bases by expanding the Songdo, Incheon, plant as well as localizing the production of finished products as the global demand is expected to grow, ensuring their stable supply to overseas markets, it said.
According to the agreement, Celltrion will commission Baxter Biopharma to produce finished product first, and gradually expand the items for consignment production through negotiations between the two companies, after the Korean company wins the approval for its second-generation products, Truxima and Hurzuma.
"With the CMO contract, Celltrion hopes it will be able to respond flexibly to U.S. demand by securing production bases in America, the world's largest biopharmaceutical market,” a company official said. "We plan to seek long-term cooperation with Baxter BioPharma, a global CMO specialist with complete production capabilities, including vials and pre-filled syringes.”
<© Korea Biomedical Review, All rights reserved.>